Abstract:, anidulafungin ( AFG ,and combinationsof FLC + AFG,AFG + AMB,andFLC + AMBagainst 17 C.albicans isolates obtained from the oral cavity of cancer patients. Isolates that had not been exposed to antifungals, served as a control group. Colony counts were performed at 0, 2, 4, 6, and 24 h after a brief ( 1 h ) antifungal exposure. Results: The FLC had no detectable post-antifungal effect independent of antifungal concentration and resembled drug-free FLC ( control ) . When all AMB and AFG were compared with FLC, significant variations in the post-antifungal effect were observed. Combining AFG and AMB with FLC resulted in effective activity compared to FLC alone. Combination regimens were rated as indifferent in general. Interestingly, low dosages of the AFG displayed increasing fungistatic action as it neared a fungistatic endpoint against C. albicans isolates ( n = 17 ) . Conclusion: Our findings suggest that brief exposure to AFG, in combination with FLC and AMB, at low concentrations of the medicines utilized, could be effective in the evaluation and optimization of new dosage regimens to manage candidiasis. However, future research will look at the clinical utility of our findings. albicans is the most common cause of nosocomial and are with morbidity and in However, limited therapeutic approaches against invasive candidiasis are available. The rise in antifungal resistance highlights the urgent need to develop new therapeutic options and novel this was an in regard of the showed a significant decrease in the number of loads,similar to the group with ATTAF-1 and ATTAF-2. Nevertheless, the results this study that the use of and ATTAF-2 as a therapeutic agent can exert significant in and in vivo antifungal effects C.albicans ,increasing animal and significantly decreasing loads. Conclusion: Although we have identified two new compounds, ATTAF-1 and ATTAF-2, as novel promising Candidates for the of studies of ATTAF-1 and ATTAF-2 activity and their action mechanisms in animal models are warranted to enhance our understanding and establish their efficacy. Antifungal-resistant dermatophytosis is an emerging threat with cases of chronic,recurrent infection reported from several countriesincluding India. Additionally, the rapidspread of infections involves person-to-personspread.Our results suggest that a clonal outbreak of a T. indotineae strain is circulating in multiple states in India. Current plans are to expand the geographic scope of the study by including over 10 countries from Europe, Middle East, and the Americas. This work will allow the publichealth community to better understandthe emergence and transmissionof antifungal-resistant dermatophytosis worldwide.

A dual action small molecule enhances azoles and overcomes resistance through co-targeting Pdr5 and Vma1

Repurposing the FDA‐approved Anticancer Agent Ponatinib As a Fluconazole Potentiator by Suppression of Multidrug Efflux and Pma1 Expression in a Broad Spectrum of Yeast Species

Hyper-Synergistic Antifungal Activity of Rapamycin and Peptide-Like Compounds against Candida albicans Orthogonally via Tor1 Kinase

Discovery of Novel α,β-Unsaturated Amide Derivatives as Candidate Antifungals to Overcome Fungal Resistance

Azole-triphenylphosphonium Conjugates Combat Antifungal Resistance and Alleviate the Development of Drug-Resistance

Antifungal resistance-modifying multiplexing action of Momordica charantia protein and phosphorylated derivatives on the basis of growth-dependent gene coregulation in Candida albicans

Fungus-mediated Biosynthesis of Gold Nanoparticles with Synergistic Antifungal Activity Against Multidrug-Resistant Candida Albicans

Azole Combinations and Multi-Targeting Drugs That Synergistically Inhibit Candidozyma auris

Fingolimod Potentiates the Antifungal Activity of Amphotericin B

A Dual-Targeting Antifungal is Effective Against Multidrug-Resistant Human Fungal Pathogens

An Insight into New Strategies to Combat Antifungal Drug Resistance

Synergic Effect of Deferoxamine Combined with Fluconazole Against Fluconazole-Resistant Candida Spp. Through Inhibited Cek1 MAPK Signaling Pathway

Combating Fungal Infections and Resistance with a Dual-Mechanism Luminogen to Disrupt Membrane Integrity and Induce DNA Damage

Discovery of Pyrazolone Carbothioamide Derivatives As Inhibitors of the Pdr1-KIX Interaction for Combinational Treatment of Azole-Resistant Candidiasis.

Synergistic Combinations of Antifungals and Anti-Virulence Agents to Fight Againstcandida Albicans

A First-in-Class Pyrazole-isoxazole Enhanced Antifungal Activity of Voriconazole: Synergy Studies in an Azole-Resistant Candida albicans Strain, Computational Investigation and in Vivo Validation in a Galleria mellonella Fungal Infection Model

Synergic effect of deferoxamine combined with fluconazole against fluconazole-resistant <i>Candida</i> Spp. through inhibited Cek1 MAPK signaling pathway

High-throughput Synergy Screening Identifies Microbial Metabolites As Combination Agents for the Treatment of Fungal Infections.

Small Molecule II-6s Synergises with Fluconazole Against Candida Albicans.

Synergistic Effect of the Combination of Deferoxamine and Fluconazole in Vitro and in Vivo Against Fluconazole-Resistant Candida Spp.

Multidrug-resistant Transporter Mdr1p-Mediated Uptake of a Novel Antifungal Compound.